Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$619.5M
181M shares
52-week range
$2.28 – $6.94
31% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.35%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $5.2M | $0 | $0 | $0 | $3.0M | $4.6M |
| Cost of revenue | $2.8M | $3.0M | $0 | $0 | $0 | $0 | $7.3M |
| Gross profit | −$2.8M | $2.2M | $0 | $0 | $0 | $3.0M | −$2.7M |
| Gross margin | — | 42.8% | — | — | — | 100.0% | -58.1% |
| R&D | $920.0K | $3.0M | $70.5M | $86.7M | $147.9M | $155.3M | $160.6M |
| Operating income | −$2.2M | −$932.0K | −$84.5M | −$116.5M | −$204.8M | −$202.5M | −$208.3M |
| EBITDA | −$2.2M | −$889.0K | −$165.3M | −$120.5M | −$186.6M | −$189.8M | −$195.8M |
| Net income | −$2.5M | −$3.4M | −$165.4M | −$121.8M | −$198.1M | −$195.9M | −$201.1M |
| Net margin | — | -65.5% | — | — | — | -6566.6% | -4342.4% |
| EPS (diluted) | -0.03 | -0.05 | -1.92 | -1.46 | -2.18 | -1.65 | -1.35 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $13M | $-1.00 | $-1.20–$-0.91 | 10 |
| 2027 | $23M | $-0.91 | $-1.16–$-0.69 | 7 |
| 2028 | $31M | $-0.81 | $-1.10–$-0.55 | 7 |
| 2029 | $18M | $-0.93 | $-4.11–$0.13 | 2 |
Forward consensus · source: Financial Modeling Prep
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
www.primemedicine.comNo one on the platform currently holds PRME.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 741,039 | $2.6M |
No one on the platform has traded PRME yet.
| +2.73% |
| $1.8B |
| — |
| PROKProKidney Corp. | $1.89 | +3.28% | $636M | — |
| REPLReplimune Group, Inc. | $11.20 | -3.70% | $925M | — |
Source: Financial Modeling Prep · peers by sector/industry
$PRME it would be soooo cool if this thing kept going up and didn’t have the biggest pullback ever like it does EVERY time
View on StockTwits ↗$PRME https://hcahealthcaretoday.com/2026/06/29/hca-healthcare-announces-new-england-journal-of-medicine-study-highlighting-advances-in-crispr-based-therapy-for-children/
View on StockTwits ↗$PRME https://www.investing.com/news/analyst-ratings/hc-wainwright-upgrades-prime-medicine-stock-rating-to-buy-93CH-4765072
View on StockTwits ↗$PRME need to break $4 and then soon into 4.40s all by today or tomorrow $SPY
View on StockTwits ↗$PRME Prime Medicine Raised to Buy From Neutral by HC Wainwright & Co. June 29, 2026 06:23 AM ET Dow Jones Newswires Prime Medicine Price Target Announced at $8.00/Share by HC Wainwright & Co. June 29, 2026 06:23 AM ET Dow Jones Newswires
View on StockTwits ↗$ABCL Just wondering if AI money is starting to move into actual applications like dna editing solutions $PRME or proteomics/multiomics like $QSI? Where all that compute is being put to real benefits/deliverables....
View on StockTwits ↗$NOK $PRME shareholders have a bright future ahead. Congratulations!
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.